Clinical Trial Update: PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of belinostat (PXD101) in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma has completed, with results posted in 2012; the study eval…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Belinostat (belinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2012-09-19